2026-04-29T04:10:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/156972024-09-27T08:30:57Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Farkouh, Michael E author Stone, Gregg W author Lala, Anuradha author Bagiella, Emilia author Moreno, Pedro R author Nadkarni, Girish N author Ben-Yehuda, Ori author Granada, Juan F author Dressler, Ovidiu author Tinuoye, Elizabeth O author Granada, Carlos author Bustamante, Jessica author Peyra, Carlos author Godoy, Lucas C author Palacios, Igor F author Fuster, Valentin author 2022-03-08 Clinical, laboratory, and autopsy findings support an association between coronavirus disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing to a high incidence of thrombosis in large and small blood vessels, both arterial and venous. Observational studies and randomized trials have investigated whether full-dose anticoagulation may improve outcomes compared with prophylactic dose heparin. Although no benefit for therapeutic heparin has been found in patients who are critically ill hospitalized with COVID-19, some studies support a possible role for therapeutic anticoagulation in patients not yet requiring intensive care unit support. We summarize the pathology, rationale, and current evidence for use of anticoagulation in patients with COVID-19 and describe the main design elements of the ongoing FREEDOM COVID-19 Anticoagulation trial, in which 3,600 hospitalized patients with COVID-19 not requiring intensive care unit level of care are being randomized to prophylactic-dose enoxaparin vs therapeutic-dose enoxaparin vs therapeutic-dose apixaban. (FREEDOM COVID-19 Anticoagulation Strategy [FREEDOM COVID]; NCT04512079). J Am Coll Cardiol. 2022 Mar 8;79(9):917-928 http://hdl.handle.net/20.500.12105/15697 35241226 10.1016/j.jacc.2021.12.023 1558-3597 Journal of the American College of Cardiology Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.